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1. Introduction
Understanding the clinical picture and the signs and symptoms produced by brain tumors is
complicated by the extreme heterogeneity amongst these patients. This is secondary to the
variability in size, location, pathology and rate of growth of the tumor. In general symptoms
can be broadly divided into two categories generalized or focal. Most generalized symptoms
are caused by the mass effect and resulting increased intracranial pressure or global cerebral
dysfunction caused by the lesion [1]. These typically are clues that a neurological abnormality
exists, but are not usually helpful in determining lesion localization.
2. Generalized symptoms
The most common generalized symptoms are shown in table 1. Headache is the most frequent
symptom and occurs in approximately 48-56% of brain tumor patients [2,3]. Headache patterns
and location vary greatly depending on mechanism and pathophysiology and this is described
in a subsequent section. In general, headaches can be either localized or global in nature and
the intensity and rate of progression may provide insight into the rate of growth of the lesion.
Lesions with a long history of slowly worsening symptoms over years tend to be more slow
growing and benign whereas acute onset headaches with a rapid crescendo pattern are
worrisome for a more ominous course. The classic brain tumor headache is one of a global
headache often radiating to the vertex or periorbital region which is associated with nausea
and vomiting and worse in the am (secondary to CO2 retention and subsequent vasodilation
during sleep).
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Headache 52%
Memory loss/cognitive dysfunction 35%
Seizures 32%
Personality Changes 23%
Nausea and Vomiting 13%
Table 1. The common generalized symptoms of brain tumor patients [3].
Cognitive changes are not only a common presenting symptom of brain tumors, but also tend
to persist even after treatment of the tumor and can affect the patient’s overall quality of life
and survival [4]. These neurocognitive deficits encompass memory problems, personality
changes, and mood disturbances. In some instances, these changes are drastic enough to cause
alarm for the patient or family member and lead directly to the diagnosis. These scenarios often
include sudden changes, such as the loss of skills related to executive functioning such as
paying bills, following directions, job performance or driving and automobile (figure 1).
Figure 1. MRI scan from an elderly patient with a pineal mass and associated hydrocephalus who presented with acute
confusion consisting of difficulty driving and paying bills.
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However, in other cases, these changes are slow and insidious and may often be overlooked
or attributed to other causes such as aging or stress. In some instances these issues present only
following a visit from a distant family member or friend who has not seen or interacted with
the patient recently. It is also not uncommon for these issues to remain completely unrecog‐
nized and discovered only after specific questioning and inquiry by a physician or as the result
of specialized neuropsychological testing. In fact when formal neuropsychological testing is
performed on this population of patients almost all of them show at least mild to moderate
dysfunction in at least one cognitive domain [4]. It has only been over the past decade that the
magnitude and impact that these cognitive deficits have on such patients has been truly
recognized.
A majority of cognitive processes, including planning, motivation, personality, judgment, and
abstraction, are controlled by the frontal lobe. However, a significant amount of these processes
require input from various other regions of the brain including the parietal and temporal lobes.
Therefore, neurocognitive changes are seen with tumors in multiple locations. The tools for
evaluation of cognitive deficits will be discussed in a separate section.
Like cognitive deficits, seizures are another symptom of brain tumors that may be present on
presentation, or may develop later during the disease process. Tumor-related seizures include
both general and focal seizures. The seizure semiology (pattern and symptoms) may provide
insight into lesion localization especially in cases with focal seizures. There is a distinction that
can be made in the incidence of seizures for various types of brain tumors. Patients with
primary brain tumors are more likely to present with seizures or subsequently develop them
as compared to patients with brain metastases [5]. In addition, patients with low grade gliomas
have seizures more commonly than those with high grade gliomas. One study showed as much
as a 85% rate of seizures in those with low grade gliomas as compared to 49% in those with
glioblastoma multiforme [5].
Seizures occur secondary to irritation of the cerebral cortex either from the brain tumor itself
or the surrounding peritumoral edema. Seizures can result from lesions in any area of the
cerebral cortex but are more frequently seen in patients with lesions in the frontal or temporal
lobes. Lesions in the brainstem and cerebellum almost never cause seizure activity. Seizures
in essence occur as a result of this cortical irritation which causes a “short circuit” within the
brain where depolarization rapidly spreads to surrounding areas. Seizure types are broken
down into several categories based on the symptoms at the time of seizure onset and whether
or not the seizure activity remains focused or spreads throughout the brain. Generalized
seizures are those where a large portion of the brain is affected at the onset and as a result of
this the patient becomes unresponsive at the onset. Secondary generalized seizures such as the
classic partial complex seizure are very common and frequently occur with lesions located in
the medial temporal lobe. In these cases symptoms typically start with rhythmic movement
on the side contralateral to the lesion but then eventually progress to generalized seizure
activity resulting in a loss of alertness and tonic and/or clonic movements on both sides of the
body. Patients with generalized or secondary generalized seizures almost always lose con‐
sciousness during the event and typically have a period of post-ictal confusion that can last
for minutes to hours following such events. However, a less common type of generalized
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seizure commonly referred to as absence seizures presents with brief starring spells without
motor movements. These episodes can occur hundreds of times per day and are not usually
associated with post-ictal confusion. Finally, focal seizures occur when the abnormal electrical
depolarization remains contained to a small area of the brain. Symptoms with this type of
seizure depend on the area involved but usually results in either episodic periods of uncon‐
trolled motor movement and twitching or sensory complaints. The classic Jacksonian March
Seizure is commonly seen with lesions in or around the primary motor cortex. These patients
exhibit episodes of tonic-clonic activity that typically starts in one area of the contralateral
extremity such as the distal leg and the involved activity spreads (“marches”) to include a
progressively larger area of the body (entire leg and then arm) as the seizure progresses.
Patients with focal seizures almost always retain consciousness and awareness during their
episodes [1].
Unlike patients with other causes of epilepsy, patients with lesional epilepsy secondary to a
brain tumor often progress in frequency, intensity and severity if they remain untreated. It is
not uncommon to see a patient with a low-grade glioma who had “a spell” several years ago
which was never investigated or brought to the attention of a physician until the patient suffers
either repeated or more intense attacks at a later date. The treatment of epilepsy in brain tumor
patients varies on a case to case basis. We do not generally recommend prophylactic antiepi‐
leptics on these patients for many reasons. Most importantly class I data shows that the routine
use of such medications doesn’t prevent these patients from having seizures, but does
significantly raise the incidence of drug related side effects [6]. In addition, many of these drugs
are metabolized through the cytochrome P450 pathway in the liver and can affect the bioa‐
vailability of many chemotherapeutic agents and can thus affect the efficacy and side effect
profile of these other medications [6]. We typically reserve the use of antiepileptics for patients
who present with a seizure or develop one during treatment or for rare instances of “high-
risk” patients with temporal lobe lesions who require awake mapping procedures. In these
unusual cases we may treat the patient only in the perioperative period. For patients requiring
treatment we commonly use leviteracitam unless the use of this is contraindicated. This
medication is typically well tolerated by the majority of these patients however in rare
instances it can cause or exacerbate headaches or cognitive dysfunction in this patient popu‐
lation. The duration of treatment for patients who present with seizure activity and then do
not have any further events remains controversial. In many instances the surgical removal of
the epileptogenic trigger may be enough to provide long-term control; however, we recom‐
mend continuing antiepileptic medications for at least 6 months or longer and routinely
perform EEG prior to considering discontinuation of any antiepileptic medications. If EEG is
normal or shows only diffuse changes than medications can usually be stopped safely;
however if it shows significant sharp waves or other electrical evidence of cortical irritation
than we will routinely advise patients to continue treatment for at least one to two years.
Nausea and vomiting associated with brain tumors is typically a result of the increasing ICP
from the space-occupying lesion. However, when occurring in the absence of other symptoms
it is often difficult to make the diagnosis which is typically made only after extensive workup
for other causes such as gastrointestinal issues have been ruled out. In rare instances lesions
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in the brainstem or other parts of the posterior fossa can lead to pure nausea and or vomiting
without other complaints.
3. Focal symptoms
Compared to the generalized symptoms described above, focal symptoms of brain tumors can
commonly offer clues as to the location of the lesion. This stems from the fact that focal deficits
are created from the tumor or resulting edema compressing a specific portion of the brain
parenchyma or cranial nerves. Therefore, from the knowledge of the structure and function of
the brain, we are able to use the focal deficits found on a patient’s exam to predict the location
of the tumor.
Motor deficits 33%
Language deficits or aphasia 32%
Visual deficits 22%
Sensory deficits 13%
Dizziness, balance problems or ataxia 9%
Table 2. The common focal symptoms of brain tumor patients [3].
Motor deficits from brain tumors can range from specific weakness in certain extremities to
generalized weakness throughout the body. Focal motor deficits occur from a lesion situated
in or around the precentral cortex (figure 2).
Figure 2. MRI showing lesion in motor cortex in a patient who presented with right sided weakness.
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Lesions in the prefrontal area, caudate or basal ganglia can also cause motor deficits but this
is typically more of a coordination or fine motor control issue as opposed to hemiplegia.
Deficits can also occur when the lesion affects the descending fibers associated with a specific
area of the motor cortex. These types of focal deficits are commonly very noticeable to patients
and often lead to them seeking medical attention sooner. In some cases, the tumor itself may
not be in a specific motor cortex region, but edema from the tumor extends to that region. In
those cases, weakness is typically very responsive to treatment with steroids.
Like focal motor deficits, sensory deficits are also seen when the tumor or associated edema
are lying in a region controlling sensory function such as the post-central gyrus or other areas
of the parietal lobe. Some of the common sensory deficits that are seen include: graphesthesia
abnormalities, stereoagnosis abnormalities, loss of proprioception, and abnormalities in pain
and touch sensation. Graphesthesia is the ability to determine a number or letter that is written
on the palm of the hand without watching as it is drawn. Stereoagnosis refers to the ability to
determine what an object is that is placed in the hand when the eyes are closed. Proprioception
refers to the ability to sense where in space a part of the body is. All of these abilities, along
with the ability to sense touch, pain, and temperature can be diminished when a brain tumor
is affecting the sensory areas of the parietal lobe [1].
When tumors occur in the regions of the brain controlling or contributing to speech and
language, specific forms of aphasia and language deficits can be seen. Statistics show that
language deficits of some sort occur in 30-53% of brain tumor patients [7,8]. Like all symptoms,
language function will be affected differently in brain tumor patients, but most commonly
tumors in the fronto-temporal region are responsible for causing aphasia [7].
Two regions of the brain, known as Broca’s and Wernicke’s area, are the most documented
regions for language control. In greater than 85% of people, these areas are located in the left
hemisphere, in the temporal region adjacent to the Sylvian fissure. Broca’s area is located in
the frontal operculum and typifies the expressive language control center, controlling a
person’s ability to facilitate speech. The location of Wernicke’s area is much more variable;
however, in most patients it is located in the posterior aspect of the superior or middle temporal
gyrus. It is associated with the control of receptive language, a person’s ability to understand
both written and spoken language.
The four most common types of aphasia include: Broca’s aphasia, Wernicke’s aphasia, global
aphasia and anomic aphasia. A brain tumor causing Broca’s aphasia would limit a patient’s
ability to express their thoughts. These patients understand what they want to say, but the ability
to form fluent, sensical words and phrases has been lost. On the other hand, a lesion causing
Wernicke’s aphasia would cause a patient to create non-sensical, non-meaningful speech. They
can speak fluently, but their words and phrases have no meaning. These patients typically are
not aware of the meaningless of their speech (figure 3).
When both Broca’s and Wernicke’s area have been affected, global aphasia results. These patients
can neither express nor understand speech and language. This includes spoken language in
addition to reading and writing. This can occur with large lesions affecting both the domi‐
nant frontal and temporal lobes or from smaller lesions which affect the angular gyrus on the
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dominant side. Finally anomic aphasia occurs when a lesion damages the left temporal region
in addition to other lesions in the language pathways. This is best illustrated in a patient who
has primarily word finding and naming difficulties. Speech will be fluent to start a sentence,
but the patient will then lose the ability to produce the next word. Anomic aphasia is the most
common form of language deficit in brain tumor patients [7].
The visual pathway is not specific to one hemisphere or lobe of the brain. Rather it encompasses
both hemispheres, multiple cranial nerves, and travels from the retina posteriorly to the
occipital lobe. Therefore, there are multiple locations in which visual deficits can be created
from a brain tumor. Even compression on the optic nerve creates variability in visual deficits
depending on the location along the cranial nerve. When compression occurs at the optic
chiasm, bitemporal hemianopsia occurs, meaning that a patient is unable to see temporal
peripheral fields out of both eyes. This type of visual loss is very common in patients with
tumors in the pituitary region, particularly with non-functioning adenomas that extend into
the suprasellar space and cause compression of the optic chiasm [9] (figure 4).
However, if compression from the lesion is only on one side of the optic nerve, than visual
impairment is only experienced on the affected side. Patients can also complain of changes
related to decreased visual acuity. This can occur with lesions anywhere along the optic system.
In addition, it is a frequent complaint among patients with hydrocephalus or increased
intracranial pressure in which case it is likely secondary to papilledema. Lesions in the occipital
lobe cause a homonymous hemianopsia in which the patient loses vision in the contralateral
portion of both eyes (figure 5). The onset of visual deficits is typically very gradual, and may
not cause the patient to seek medical attention until the deficits are very severe. In fact in
patients with benign slow growing lesions symptoms may not become evident until the patient
experiences and accident from running into an object that they didn’t visualize secondary to
an enlarged blind spot.
Figure 3. MRI scan of patient presenting with Wernicke’s type aphasia.
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Figure 5. MRI scan of patient presenting with a left homonymous hemianopsia from a right occipital lesion.
Figure 4. Coronal MRI of a patient with a large pituitary mass compressing the optic chiasm causing bitemporal hemi‐
anopsia.
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Cranial nerve dysfunction is much less common than the other above symptoms. These
typically occur with lesions affecting the skull base and in many instances multiple cranial
nerves may be involved. In general the cranial nerves with pure motor functions (i.e. Facial
nerve) are much more resistant to compressive forces than sensory nerves (i.e. Acoustic and
vestibular nerves) (figure 6). In patients with metastatic disease the occurrence of multiple
cranial neuropathies is an ominous sign and usually signifies the presence of leptomeningeal
disease.
Figure 6. Axial post contrast MRI of patient with a small right acoustic neuroma who presented with hearing loss.
4. Headaches
Headaches are probably the most common complaint among brain tumor patients. Headaches
can arise from many different pathological reasons. In some instances the headaches are
unrelated to the imaging abnormalities and thus may not improve with treatment whereas in
others the headaches are directly related to the pathological abnormalities.
In many instances the headaches are the result of increased intracranial pressure. This
headache pattern is often associated with either large tumors or those lesions that have
significant surrounding peritumoral edema (figure 7). The skull is a fixed rigid space with a
limited volume. Therefore any changes in that volume directly affect the pressure within the
skull. During early stages or with slowly growing lesions the CNS has the ability to autore‐
gulate and compensate for these changes in tumor or edema volume by decreasing spinal fluid
or changes in venous engorgement. However, sudden rapid changes in tumor size or edema
can cause changes that cannot be overcome by these typical compensatory mechanisms and
thus cause a dramatic change in intracranial pressure (ICP). This relationship of pressure and
volume in the skull is referred to as the Monroe-Kelli Doctrine [1].







Figure 7. Axial T2-weighted and post contrast T1-weighted MRI scan showing significant edema and midline shift sec‐
ondary to a tumor and surrounding edemawhich resulted in headache secondary to increased ICP
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Typically headaches associated with this type of pathology are reported as global or frequently
refer pain to the convexity or bifrontal/periorbital region. These headaches are usually
progressive with time and are crescendo in nature. The speed at which they worsen varies
depending on the rate of change in ICP. These headaches are usually worse in the morning
and often associated with nausea and or vomiting. Vague visual complaints, likely the result
of increased pressure in the optic nerve sheath, are often common.
Some lesions result in obstructive hydrocephalus (figure 1). The pattern and disease progres‐
sion are often similar to headaches from more general increased ICP. These patients often have
cognitive deficits as a result of involvement of the lateral ventricles and frontal horns. In severe
cases alterations in mental status can occur and at times rapidly progress to death if emergent
interventions are not instituted.
Headaches as the result of dural inflammation or irritation tend to me more focal. This can be
the result of focal involvement of the dura by lesions such as meningiomas or metastasis or
from stretching of the dura from tumor growth. A majority of the dura in innervated by the
trigeminal nerve. As a result pain can at times be referred to the face, preauricular or periorbital
region.
However, in most cases the headaches are located unilaterally ipsilateral to the pathology and
in some instances directly correlated with lesion location. In my experience headaches that are
directly correlated with the location of imaging abnormalities almost always improve with
surgical resection.
Tumors in the sellar region can commonly cause stretching of the diaphragm sella (figure 8).
These headaches commonly radiate to the periorbital or bifrontal region. The intensity and
frequency of these types of headaches commonly fluctuate and can be sporadic in nature likely
do to transient changes in local inflammation or pressure in the lesion itself.
Tumors that invade or compress the trigeminal nerve typically cause a very classic head‐
ache syndrome. Many of these patients experience facial pain syndromes similar to classic
trigeminal neuralgia. This can often be dysesthetic in nature and frequently can become very
severe and debilitating. The pain is always on the side of the lesion unless there is involve‐
ment of  the brainstem. Unlike classic  trigeminal  neuralgia patients pain related to these
lesions  typically  does  not  respond  to  medical  management  (gabapentin,  pregabalin  or
carbamazepine) (figure 9).
In rare instances tumors can be large enough to compress or stretch the large arteries in the
brain. Headaches from this cause are infrequent and vary in nature and symptomatology. On
the other hand headaches as the result of tumor bleeding tend to be very classic. These
headaches are often thunderclap or sudden onset in nature and occur instantaneously with a
high intensity. Mental status changes and nausea and vomiting may accompany this type of
headache depending on the volume and degree of hemorrhage (figure 10). Table three shows
the most common histologies for brain metastasis which result in hemorrhage.
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Figure 8. Coronal MRI of a patient with a small pituitary macroadenoma who presented with headache likely the re‐
sult of stretching of the diaphragm sella.
Figure 9. Axial post contrast MRI of patient with left sided facial pain who was found to have a small trigeminal neu‐
roma compressing the trigeminal nerve.
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Table 3. Most common histologies for brain metastasis that result in hemorrhage
Lesions located in the posterior fossa can cause headaches that refer pain to the vertex
especially if there is associated hydrocephalus. In addition, pain may also be referred to the
auricular and post auricular region secondary to innervation of the petrous dura and tentori‐
um. These patients may also complain of pain in the suboccipital region. In rare instances of
tonsilar herniation either from posterior fossa lesions or hydrocephalus patients may complain
of severe neck pain at the base of the skull which worsens with extension.
The determination of which headache patient to image is always a difficult decision for the
primary care or emergency room doctor as there are many more patients who complain of
headaches who don’t have intracranial pathology that those who do. My recommendations
have always been that for adult patients who previously have not had significant headaches
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but then start having gradually progressive headaches that imaging should be strongly
considered. Patients with rapidly deteriorating headaches or those with thunderclap onset
deserve more urgent evaluation. A strong index of suspicion should also be entertained when
new headaches occur with nausea and vomiting and persist despite routine headache man‐
agement. Headaches associated with any other neurological finding or seizure activity also
demand urgent imaging. In most instances MRI with and without contrast is the gold standard
as CT scanning even when performed with contrast can have significant false negative rates.
CT scanning may be adequate when intracranial hemorrhage or hydrocephalus are of concern
based on clinical suspicion.
5. Cognitive evaluation for brain tumor patients
A majority of patients harboring brain tumors experience changes in cognitive or high level
executive functioning [10-14]. Many patients may complain of subjective deficits which often
are difficult to characterize, while others can slowly develop large abnormalities and be
unaware of the slowly progressive changes (figure 11).
Unless patients are exhibiting major confusion and disorientation these complaints often go
unassessed and unaddressed for these patients. In addition, most will exhibit at least partial
improvement if a cognitive rehabilitation program is instituted before symptoms become too
devastating [15].
Objective screening tests are limited and vary in efficacy in this patient population. Extensive
neuropsychological batteries are time consumptive and require a trained neuropsychologist
which is not available at most major brain tumor centers or smaller community treatment
facilities. In addition, these deficits can change with time and are affected by all treatment
modalities: surgery, radiation and chemotherapy. Therefore any reliable screening tool must
also take into account the effect of “learning” from prior administrations.
Not until the past decade has the importance of assessing cognitive function and evaluating
the impact of treatment on such function come into the forefront, despite the known association
with cognitive functioning on quality of life and overall survival [16-18]. Only recently have
prospective studies incorporated some aspect of cognitive evaluation in their study design.
The mini-mental status evaluation (MMSE) is the most frequently used tool in clinical practice
as well as for many large research studies. This test has numerous drawbacks including
extremely low sensitivity and specificity in this patient population. In addition a “ceiling
effect” exists [4]. Many patients score normal results on this test despite having significant
cognitive impairments.
For the past five years I have been using the Montreal Cognitive Assessment Tool (MoCA)
with my tumor patients. This is a free screening tool (available at www.mocatest.org) can be
administered by office staff or physicians with minimal training and excellent inter-observer
reliability. This tool assesses several aspects of cognitive function including: executive
function, visuo-spatial function, naming, memory, attention, abstraction, language, orienta‐




Figure 11. Axial post-contrast T1-weighted and FLAIR MRI in patient with a large olfactory groove meningioma who
presented with cognitive dysfunction.
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tion; and has been used extensively as a screening tool and for serial examinations for
numerous different pathological conditions from dementia to heart failure.
The MoCA is more sensitive than the MMSE for detecting mild cognitive impairment (MCI)
[19-21]. Olson compared the efficacy of MoCA vs MMSE in a group of patients with brain
metastasis by administering both tests to patients at a similar time point after diagnosis of their
brain metastasis. Ninety-eight percent of patients completed the test in less than 15 minutes,
and 88% of patients took less than 10 minutes. Based on the results of the study (using normal
cutoff scores for both tests) 80% of patients were classified as having at least mild cognitive
impairment on the MoCA (score <26) vs. 30% using the MMSE (score <26) [22].
In 2011 the same group reported the results of 58 brain metastasis patients who were studied
prospectively [4]. Once again both groups were administered MoCA and MMSE tests, 67% of
the patients also underwent formal neuropsychological assessment (NPA) which consisted of
a battery of tests taking 3-4 hours to complete. This formal testing was performed within 2
weeks of administration of the screening tests. Study analysis showed that only 7% of patients
scored normal on the NPA and an additional 38% had borderline results, the remainder of the
patients had cognitive impairment in greater than two domains. MMSE results showed
abnormal cognitive function in only 12.8% and MoCA showed impairment in 53.8%. Thus it
is clearly illustrated based on the poor sensitivity that the MMSE is a poor screening tool for
determining cognitive impairment in these patients and has limited value. The MoCA was
more sensitive in determining mild cognitive impairment but still failed to illustrate all cases
[4]. Finally, in yet another study they were able to show that the results of the MoCA were
highly correlated with overall survival in patients undergoing treatment for brain metastasis
but failed to show a relationship of survival to MMSE results [22].
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